API market to touch US$185.9 billion by 2020
Global API market driven by the rising abbreviated new drug applications and the growth in filing drug master files from several Indian firms, says Transparency Market Research.
A new Transparency Market Research report states that the global active pharmaceuticals ingredients (APIs) market stood at US$119.7 billion in 2014 and is predicted to reach US$185.9 billion by 2020. It is expected to expand at a CAGR of 6.50% from 2014 to 2020. The title of the report is "Active Pharmaceutical Ingredients (API) Market: (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic Area) — Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014–2020".
The global pharmaceutical industry has suffered enormously due to patent expiry of blockbuster drugs in the past few years. However, this has facilitated a surge in the demand for low-cost substitutes across the globe resulting in a boost to active pharmaceutical ingredient (API) manufacturing. The approvals of biosimilars in Europe has added to the total API market revenue, and the recent approval of Novartis' filgrastim biosimilar in the US is expected to continue the upward trend in this market. The overall global APIs market was valued at USD 119.7 billion in 2013 and is anticipated to reach USD 185.9 billion by 2020, expanding at a CAGR of 6.5% during the forecast period from 2014 to 2020.
The global APIs market is driven by the rising abbreviated new drug applications (ANDA). In the past few years, the growth in ANDAs has in turn fuelled the demand for APIs. In addition to this, the growth in filing drug master files (DMFs) from several Indian firms has fueled the overall APIs market. On the other hand, the global APIs market will be constrained by the strict European Union (EU) regulatory policies.
As per the report, the APIs market is fuelled by the rising abbreviated new drug applications and the increasing drug master file filing via Indian companies. The prime opportunity seen in the market is the patent expiry of promising biological drugs. On the other hand, factors such as the stringent EU regulatory policies will impede the growth of the APIs market in the coming years.
On the basis of type of manufacturing, the market is segmented into API contract manufacturing and captive or in-house API manufacturing. Amongst these, the segment of captive or in-house API manufacturing is experiencing a rapid decline in the market for APIs owing to its lack of profitability for the manufacturer and rising degree of competition in the market. Pharmaceutical companies are inclined towards API contract manufacturing rather than in-house API manufacturing owing to the increasing costs of research and development, and the pressure to maintain low prices of finished goods. Thus, outsourcing of API production is increasingly being preferred by manufacturers.
On the basis of type of API, the market is segmented into biological APIs and synthetic chemical APIs. Amongst these, the segment of biological APIs is experiencing the most significant growth rate owing to the huge number of pharmaceutical companies involved in this segment.
The chief players dominant in the market are Boehringer Ingelheim Group, Dr Reddy's Laboratories, Cambrex, BASF, Lonza, Hospira, Mylan, Teva Pharmaceutical Industries, Novartis, and Pfizer.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance